Table 1.
Baseline demographic and clinical characteristics of patients with prostate cancer (n = 87).
| Characteristics | Microsphere (n = 44) | Implant (n = 43) | P value |
|---|---|---|---|
| Median age (years) | 71 (55, 90) | 73 (55, 88) | 0.1289 |
| Stage of disease, n (%) | |||
| Localized | 13 (29.5) | 1 (2.3) | 0.0244 |
| Locally advanced | 7 (15.9) | 4 (9.3) | 0.5378 |
| Metastatic | 18 (40.9) | 33 (76.7) | 0.1206 |
| None | 6 (13.6) | 5 (11.6) | 0.8514 |
| Gleason grade, n (%) | |||
| 6 | 2 (4.5) | 2 (4.7) | 0.9862 |
| 7 | 9 (20.5) | 9 (20.9) | 0.9724 |
| 8 | 12 (27.3) | 10 (23.3) | 0.791 |
| 9-10 | 12 (27.3) | 10 (23.3) | 0.791 |
| Missing | 9 (20.5) | 12 (27.9) | 0.6149 |
| ECOG performance status, n (%) | |||
| 0 | 34 (77.3) | 28 (65.1) | 0.6329 |
| 1 | 10 (22.7) | 15 (34.9) | 0.452 |
| Prior anticancer therapy, n (%) | |||
| Yes | 19 (43.2) | 10 (23.3) | 0.2524 |
| No | 25 (56.8) | 33 (76.7) | 0.4183 |
| Type of prior therapy, n (%) | |||
| Radiotherapy | 8 (18.2) | 21 (48.8) | 0.0783 |
| Chemotherapy | 5 (11.4) | 5 (11.6) | 0.9789 |
| None | 31 (70.5) | 17 (39.5) | 0.1674 |
Data are presented as median (range) or n (%). ECOG, Eastern Cooperative Oncology Group; n, number of patients. P values were calculated using the Wilcoxon rank-sum test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables, as appropriate. P values are descriptive because of the retrospective study design and limited sample size.